Osborn Williams & Donohoe LLC lessened its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 9.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,537 shares of the biopharmaceutical company’s stock after selling 5,760 shares during the quarter. Osborn Williams & Donohoe LLC’s holdings in Bristol-Myers Squibb were worth $3,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the business. Beacon Financial Group grew its stake in Bristol-Myers Squibb by 1.6% in the 3rd quarter. Beacon Financial Group now owns 96,488 shares of the biopharmaceutical company’s stock valued at $3,985,000 after purchasing an additional 1,541 shares during the period. McQueen Ball & Associates Inc. bought a new position in Bristol-Myers Squibb in the 3rd quarter valued at $214,000. Curbstone Financial Management Corp grew its stake in Bristol-Myers Squibb by 103.3% in the 3rd quarter. Curbstone Financial Management Corp now owns 12,814 shares of the biopharmaceutical company’s stock valued at $817,000 after purchasing an additional 6,510 shares during the period. Bridges Investment Management Inc. grew its stake in Bristol-Myers Squibb by 8.7% in the 3rd quarter. Bridges Investment Management Inc. now owns 14,214 shares of the biopharmaceutical company’s stock valued at $906,000 after purchasing an additional 1,143 shares during the period. Finally, Perpetual Ltd grew its stake in Bristol-Myers Squibb by 10.8% in the 2nd quarter. Perpetual Ltd now owns 16,444 shares of the biopharmaceutical company’s stock valued at $916,000 after purchasing an additional 1,600 shares during the period. Hedge funds and other institutional investors own 69.82% of the company’s stock.

In related news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

A number of research analysts have issued reports on BMY shares. Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. Goldman Sachs Group reiterated a “buy” rating and set a $65.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research note on Wednesday, November 1st. Finally, Barclays increased their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $64.93.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.41 on Friday. The stock has a market capitalization of $102,154.63, a PE ratio of 21.09, a P/E/G ratio of 2.37 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the company posted $0.77 EPS. analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.

COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Holdings Cut by Osborn Williams & Donohoe LLC” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-holdings-cut-by-osborn-williams-donohoe-llc/1769404.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.